TABLE 2.
Inhibitory effects of DQ HME formulations on Plasmodium berghei ANKA expressing luciferase at the liver stagea
| Antimalarials | PQ IC50 (μM) |
AQ IC50 (nM) |
||
|---|---|---|---|---|
| Mean (n = 3) | SD | Mean (n = 3) | SD | |
| Day 01 | 1.882 | 0.584 | 9.497 | 2.239 |
| Formulation/days tested | F8 IC50 (nM) | F15 IC50 (nM) | ||
| Day 01 | 0.342 | 0.073 | 0.349 | 0.054 |
| Day 30 | 0.168 | 0.086 | 0.195 | 0.035 |
| Day 64 | 0.432 | 0.034 | 0.401 | 0.012 |
| Day 70 | 0.312 | 0.060 | 0.296 | 0.023 |
| Day 79 | 0.171 | 0.064 | 0.176 | 0.015 |
a
HepG2 cells were cultured and infected by the sporozoites (SPZ) isolated from salivary glands of infected mosquitoes. Aqueous suspensions of F8 and F15 were stored at 4°C and tested on different days after they were made to assess the stability of the formulations. The results are expressed by the half-maximal inhibition concentration (IC50). In vitro potency of HME DQ against liver-stage Plasmodium between day 1 and all other days was not significantly different (P > 0.05). AQ, atovaquone; PQ, primaquine.